VINC: Vincerx Pharma, Inc. Stock

by  •  • Comments Off on VINC: Vincerx Pharma, Inc. Stock

SIC 2834 – Pharmaceutical Preparations

Valuation
Market Cap ($M) 1.97
Enterprise Value ($M) -0.97
Book Value ($M) 9.11
Book Value / Share 4.07
Price / Book 0.22
NCAV ($M) 5.91
NCAV / Share 2.64
Price / NCAV 0.33

Profitability (mra)
Return on Invested Capital (ROIC) -2.52
Return on Assets (ROA) -1.48
Return on Equity (ROE) -2.41

Liquidity (mrq)
Quick Ratio 2.17
Current Ratio 2.17

Balance Sheet (mrq) ($M)
Current Assets 11.75
Assets 14.95
Liabilities 5.84
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income 0.00
Net Income 0.00
Earnings Per Share Basic And Diluted n/a

Cash Flow Statement (mra) ($M)
Cash From Operations 0.00
Cash from Investing 0.00
Cash from Financing 0.00

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)		 Change
(%)
02-14 13G/A Armistice Capital, Llc
02-11 13G/A Long Focus Capital Management, Llc 0.00 -100.00
11-14 13G/A Bank Of America Corp /de/ 0.00 -99.98
11-13 13G/A Prosight Management, LP 5.00 -32.78
04-09 13G/A Goldman Sachs Group Inc 3.00 -63.06
2024-02-13 13G/A Affinity Asset Advisors, LLC 0.00 -100.00

Top 13F Investors Shares
(1000)		 Change
(%)		 Value
($1000)		 Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-11-12 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION R
2024-08-08 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT
2024-05-14 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPOR
2024-03-29 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PUR

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2025-03-07 13,462 122,048 11.03
2025-03-06 22,023 73,709 29.88
2025-03-05 44,532 110,409 40.33
2025-03-04 40,084 128,452 31.21

(click for more detail)

Similar Companies
UPC – Universe Pharmaceuticals INC UPXI – Upexi, Inc.
VERU – Veru Inc. VKTX – Viking Therapeutics, Inc.
VRPX – Virpax Pharmaceuticals, Inc.


Financial data and stock pages provided by
Fintel.io